相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The characterisation of subjective cognitive decline
Frank Jessen et al.
LANCET NEUROLOGY (2020)
Is the p3 Peptide (Aβ17-40, Aβ17-42) Relevant to the Pathology of Alzheimer's Disease?
Ariel J. Kuhn et al.
JOURNAL OF ALZHEIMERS DISEASE (2020)
Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals
Reisa A. Sperling et al.
JAMA NEUROLOGY (2020)
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Harald Hampel et al.
FRONTIERS IN IMMUNOLOGY (2020)
APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline
Axel Montagne et al.
NATURE (2020)
LRP1 is a master regulator of tau uptake and spread
Jennifer N. Rauch et al.
NATURE (2020)
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
Francesco Panza et al.
NATURE REVIEWS NEUROLOGY (2020)
Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline
Joanne Ryan et al.
NEUROLOGY (2020)
Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts
P. M. Rossini et al.
CLINICAL NEUROPHYSIOLOGY (2020)
Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer's disease?
Bruno P. Imbimbo et al.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2020)
ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes
Anja Soldan et al.
NEUROLOGY (2019)
Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?
Francesco Panza et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2019)
Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease
David Henley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease
Michael F. Egan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease
Dan-Dan Li et al.
FRONTIERS IN NEUROSCIENCE (2019)
Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia
Clifford R. Jack et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging
Prashanthi Vemuri et al.
ANNALS OF NEUROLOGY (2019)
Time to test antibacterial therapy in Alzheimer's disease
Francesco Panza et al.
BRAIN (2019)
Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression
Xinyi Wang et al.
CELL RESEARCH (2019)
Structure-activity relationships of flurbiprofen analogues as stabilizers of the amyloidogenic protein transthyretin
Valentina Loconte et al.
JOURNAL OF STRUCTURAL BIOLOGY (2019)
Investigational BACE inhibitors for the treatment of Alzheimer's disease
Bruno P. Imbimbo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?
Francesco Panza et al.
ANNALS OF NEUROLOGY (2019)
Efficacy and safety of alisporivir for the treatment of hepatitis C infection
Carol Stanciu et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
A critical appraisal of amyloid-βtargeting therapies for Alzheimer disease
Francesco Panza et al.
NATURE REVIEWS NEUROLOGY (2019)
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis
Gregory Klein et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease
Adam J. Schwarz et al.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2019)
Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress
Merce Boada et al.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2019)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults
Nancy J. Donovan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Effect of Sleep on Overnight Cerebrospinal Fluid Amyloid beta Kinetics
Brendan P. Lucey et al.
ANNALS OF NEUROLOGY (2018)
The A beta protofibril selective antibody mAb158 prevents accumulation of A beta in astrocytes and rescues neurons from A beta-induced cell death
Sofia Sollvander et al.
JOURNAL OF NEUROINFLAMMATION (2018)
Amyloid pathology in the progression to mild cognitive impairment
Philip S. Insel et al.
NEUROBIOLOGY OF AGING (2018)
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
Lawrence S. Honig et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cromolyn Reduces Levels of the Alzheimer's Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis
Can Zhang et al.
SCIENTIFIC REPORTS (2018)
The Physiological Roles of Amyloid-beta Peptide Hint at New Ways to Treat Alzheimer's Disease
Holly M. Brothers et al.
FRONTIERS IN AGING NEUROSCIENCE (2018)
Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals Findings From the Harvard Aging Brain Study
Jennifer S. Rabin et al.
JAMA NEUROLOGY (2018)
Aroylhydrazones constitute a promising class of 'metal-protein attenuating compounds' for the treatment of Alzheimer's disease: a proof-of-concept based on the study of the interactions between zinc(II) and pyridine-2-carboxaldehyde isonicotinoyl hydrazone
Daphne S. Cukierman et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2018)
Mitochondrial Pharmacology of Dimebon (Latrepirdine) Calls for a New Look at its Possible Therapeutic Potential in Alzheimer's Disease
Schamim H. Eckert et al.
AGING AND DISEASE (2018)
Peripheral immune system in aging and Alzheimer's disease
Wei Cao et al.
MOLECULAR NEURODEGENERATION (2018)
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease
John A. Hey et al.
CLINICAL PHARMACOKINETICS (2018)
Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons
Michael C. Donohue et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis
Taro Kishi et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Levetiracetam Alters Oscillatory Connectivity in Alzheimer's Disease
Christian S. Musaeus et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Discovery and Development of 1-[(2-Bromophenyl)sulfony1]-5methoxy-3-[(4-methyl-1-piperazinyl)methy1]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer's Disease
Ramakrishna Nirogi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease
Susanne Ostrowitzki et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid β Combination for Alzheimer's Disease
Takayuki Kondo et al.
CELL REPORTS (2017)
Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum
David T. Jones et al.
CORTEX (2017)
Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β
Elizabeth C. Mormino et al.
ALZHEIMERS & DEMENTIA (2017)
Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels
Yo-El S. Ju et al.
BRAIN (2017)
CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects
Lixia Qiang et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2017)
The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model
Randall J. Bateman et al.
ALZHEIMERS & DEMENTIA (2017)
Incidence and Impact of Subclinical Epileptiform Activity in Alzheimer's Disease
Keith A. Vossel et al.
ANNALS OF NEUROLOGY (2016)
Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients
Francesco Panza et al.
EXPERT OPINION ON EMERGING DRUGS (2016)
Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium
Davide Seripa et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
The amyloid cascade hypothesis: are we poised for success or failure?
Eric Karran et al.
JOURNAL OF NEUROCHEMISTRY (2016)
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
Jinping Wang et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Effects of Heart Bypass Surgery on Plasma Aβ40 and Aβ42 Levels in Infants and Young Children
Yaoqin Hu et al.
MEDICINE (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
Safety and tolerability of BAN2401-a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody
Veronika Logovinsky et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium
Davide Seripa et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models
Yvonne Bouter et al.
ACTA NEUROPATHOLOGICA (2015)
Beta-amyloid deposition in chronic traumatic encephalopathy
Thor D. Stein et al.
ACTA NEUROPATHOLOGICA (2015)
Neuroinflammation in Alzheimer's disease
Michael T. Heneka et al.
LANCET NEUROLOGY (2015)
The Alzheimer disease market
XiaoXiao Qian et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
An Assessment of Possible Neuropathology and Clinical Relationships in 46 Sporadic Amyotrophic Lateral Sclerosis Patient Autopsies
Grant Coan et al.
NEURODEGENERATIVE DISEASES (2015)
Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial
NEUROLOGY (2015)
Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance
Arnold Bakker et al.
NEUROIMAGE-CLINICAL (2015)
The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-beta Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice
Stina Tucker et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
A Food and Drug Administration-approved Asthma Therapeutic Agent Impacts Amyloid β in the Brain in a Transgenic Model of Alzheimer Disease
Yukiko Hori et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
The Alzheimer's disease mitochondrial cascade hypothesis: Progress and perspectives
Russell H. Swerdlow et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2014)
Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward
Francesco Panza et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease
Francesco Panza et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2014)
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The A4 Study: Stopping AD Before Symptoms Begin?
Reisa A. Sperling et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The Preclinical Alzheimer Cognitive Composite Measuring Amyloid-Related Decline
Michael C. Donohue et al.
JAMA NEUROLOGY (2014)
Effect of 1 Night of Total Sleep Deprivation on Cerebrospinal Fluid β-Amyloid 42 in Healthy Middle-Aged Men A Randomized Clinical Trial
Sharon Ooms et al.
JAMA NEUROLOGY (2014)
Open-heart surgery increases cerebrospinal fluid levels of Alzheimer-associated amyloid β
B. Reinsfelt et al.
ACTA ANAESTHESIOLOGICA SCANDINAVICA (2013)
The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques
Patty C. Kandalepas et al.
ACTA NEUROPATHOLOGICA (2013)
Rational heterodoxy: Cholesterol reformation of the amyloid doctrine
Michael A. Castello et al.
AGEING RESEARCH REVIEWS (2013)
Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease
Serge Gauthier et al.
ALZHEIMERS & DEMENTIA (2013)
Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease
Carolyn W. Zhu et al.
ALZHEIMERS & DEMENTIA (2013)
Antiepileptics Topiramate and Levetiracetam Alleviate Behavioral Deficits and Reduce Neuropathology in APPswe/PS1dE9 Transgenic Mice
Jian-Quan Shi et al.
CNS NEUROSCIENCE & THERAPEUTICS (2013)
CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo-Controlled Study
Joel Ross et al.
CURRENT ALZHEIMER RESEARCH (2013)
Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors
Giuseppe Zanotti et al.
FEBS LETTERS (2013)
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Stephanie J. B. Vos et al.
LANCET NEUROLOGY (2013)
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
Clifford R. Jack et al.
LANCET NEUROLOGY (2013)
Brain Ischemia Activates β- and γ-Secretase Cleavage of Amyloid Precursor Protein: Significance in Sporadic Alzheimer's Disease
Ryszard Pluta et al.
MOLECULAR NEUROBIOLOGY (2013)
Immunotherapy for Alzheimer's disease: hoops and hurdles
Cynthia A. Lemere
MOLECULAR NEURODEGENERATION (2013)
Deciphering the mechanism underlying late-onset Alzheimer disease
Dimitrije Krstic et al.
NATURE REVIEWS NEUROLOGY (2013)
Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial
S. M. Mills et al.
REVUE NEUROLOGIQUE (2013)
Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation
Ayman ElAli et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2013)
Is Alzheimer's disease amyloidosis the result of a repair mechanism gone astray?
Tyler A. Kokjohn et al.
ALZHEIMERS & DEMENTIA (2012)
Safety and biomarker effects of Solanezumab in patients with Alzheimer's disease
Martin Farlow et al.
ALZHEIMERS & DEMENTIA (2012)
Lower CSF Amyloid Beta Peptides and Higher F2-lsoprostanes in Cognitively Intact Elderly Individuals With Major Depressive Disorder
Nunzio Pomara et al.
AMERICAN JOURNAL OF PSYCHIATRY (2012)
Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
Susanne Ostrowitzki et al.
ARCHIVES OF NEUROLOGY (2012)
Soluble oligomers and fibrillar species of amyloid β-peptide differentially affect cognitive functions and hippocampal inflammatory response
Yan He et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease
Grazia D'Onofrio et al.
EXPERT OPINION ON DRUG DISCOVERY (2012)
Solanezumab for the treatment of mild-to-moderate Alzheimer's disease
Bruno P. Imbimbo et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2012)
Amyloid precursor protein (APP) contributes to pathology in the SOD1G93A mouse model of amyotrophic lateral sclerosis
J. Barney Bryson et al.
HUMAN MOLECULAR GENETICS (2012)
Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
Bernd Bohrmann et al.
JOURNAL OF ALZHEIMERS DISEASE (2012)
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Robert D. Bell et al.
NATURE (2012)
Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment
Arnold Bakker et al.
NEURON (2012)
3,3′,4′,5,5′-Pentahydroxyflavone is a potent inhibitor of amyloid β fibril formation
Hiroko Ushikubo et al.
NEUROSCIENCE LETTERS (2012)
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease
Darin Jaturapatporn et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease
Marwan N. Sabbagh et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2011)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
Longitudinal Assessment of A beta and Cognition in Aging and Alzheimer Disease
Victor L. Villemagne et al.
ANNALS OF NEUROLOGY (2011)
Anti-β-Amyloid Immunotherapy for Alzheimer's Disease: Focus on Bapineuzumab
Francesco Panza et al.
CURRENT ALZHEIMER RESEARCH (2011)
Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
Eric M. Reiman et al.
JOURNAL OF ALZHEIMERS DISEASE (2011)
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
S. Salloway et al.
NEUROLOGY (2011)
Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid beta After a Single Administration of an Amyloid beta Monoclonal Antibody in Subjects With Alzheimer Disease
Eric R. Siemers et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease
Eduardo Cumbo et al.
EPILEPSY & BEHAVIOR (2010)
Is Brain Amyloid Production a Cause or a Result of Dementia of The Alzheimer's Type?
Robert G. Struble et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Reimagining Alzheimer's Disease-An Age-Based Hypothesis
Karl Herrup
JOURNAL OF NEUROSCIENCE (2010)
Traumatic brain injury and amyloid-beta pathology: a link to Alzheimer's disease?
Victoria E. Johnson et al.
NATURE REVIEWS NEUROSCIENCE (2010)
Treatment Strategies Targeting Excess Hippocampal Activity Benefit Aged Rats with Cognitive Impairment
Ming Teng Koh et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer Disease: 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Trial Study
Richard C. Mohs et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2009)
The Common Inhalational Anesthetic Sevoflurane Induces Apoptosis and Increases β-Amyloid Protein Levels
Yuanlin Dong et al.
ARCHIVES OF NEUROLOGY (2009)
Amyloid β-Induced Neuronal Hyperexcitability Triggers Progressive Epilepsy
Rimante Minkeviciene et al.
JOURNAL OF NEUROSCIENCE (2009)
A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease
Patrizio Pasqualetti et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2009)
Alzheimer disease pathology as a host response
Rudy J. Castellani et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2008)
Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study
Rachelle S. Doody et al.
LANCET (2008)
Protective effects of NSAIDs on the development of Alzheimer disease
Steven C. Vlad et al.
NEUROLOGY (2008)
Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid β protein
Tatsuhiro Akaishi et al.
NEUROSCIENCE LETTERS (2008)
Amyloid-β in Alzheimer disease:: The null versus the alternate hypotheses
Hyoung-gon Lee et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
A marine-derived acidic oligosaccharide sugar chain specifically inhibits neuronal cell injury mediated by beta-amyloid-induced astrocyte activation in vitro
Shaohua Wang et al.
NEUROLOGICAL RESEARCH (2007)
Control of peripheral nerve myelination by the β-secretase BACE1
Michael Willem et al.
SCIENCE (2006)
Synthesis and biological activity of flurbiprofen analogues as selective inhibitors β-amyloid1-42 secretion
I Peretto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen
R Lalonde et al.
BEHAVIOURAL BRAIN RESEARCH (2005)
Acidic oligosaccharide sugar chain, a marine-derived acidic oligosaccharide, inhibits the cytotoxicity and aggregation of amyloid beta protein
JF Hu et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2004)
Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation
A Lleó et al.
NATURE MEDICINE (2004)
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
JC Dodart et al.
NATURE NEUROSCIENCE (2002)
Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease
OL Lopez et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2002)
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
S Weggen et al.
NATURE (2001)
Practice parameter: Management of dementia (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology
RS Doody et al.
NEUROLOGY (2001)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease
GP Lim et al.
JOURNAL OF NEUROSCIENCE (2000)
分享论文
